Real world effectiveness, adherence, and treatment discontinuation in patient with hepatitis C virus (HCV) treated with Ledipasvir/sofosbuvir.

Trial Profile

Real world effectiveness, adherence, and treatment discontinuation in patient with hepatitis C virus (HCV) treated with Ledipasvir/sofosbuvir.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 06 Oct 2017 New trial record
    • 01 Sep 2017 Results assessing real world effectiveness, adherence, and treatment discontinuation in patient with hepatitis C virus (HCV) treated with Ledipasvir/sofosbuvir, were published in the Infectious Diseases and Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top